Search research articles
Contact Us
Filters
Showing results (101-110 of 117) with videos related to
Page
of 12
Sort By:
Clinical Lymphoma, Myeloma & Leukemia
|
June 26, 2025
Health-Related Quality of Life With Odronextamab Monotherapy for Relapsed/Refractory Follicular Lymphoma in the ELM-2 Study
Benoit Tessoulin, James Harnett, Seok-Goo Cho, et al.
Oncotarget
|
May 29, 2018
Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma
Alessandro Broccoli, Beatrice Casadei, Alice Morigi, et al.
Leukemia
|
August 30, 2022
Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients
Barbara Mora, Paola Guglielmelli, Andrew Kuykendall, et al.
Hematological Oncology
|
May 25, 2022
Ibrutinib dose intensity in high-risk chronic lymphocytic leukemia
Gabriela Forestieri, Lodovico Terzi di Bergamo, Marina Deodato, et al.
Blood Advances
|
June 5, 2023
A Fondazione Italiana Linfomi cohort study of R-COMP vs R-CHOP in older patients with diffuse large B-cell lymphoma
Annalisa Arcari, Lugi Rigacci, Alessandra Tucci, et al.
British Journal of Haematology
|
November 9, 2018
Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death
Carlo Visco, Maria C Tisi, Andrea Evangelista, et al.
Eclinicalmedicine
|
April 18, 2024
Marginal zone lymphoma international prognostic index: a unifying prognostic index for marginal zone lymphomas requiring systemic treatment
Luca Arcaini, Côme Bommier, Juan Pablo Alderuccio, et al.
Hematological Oncology
|
October 20, 2022
SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort
Michele Merli, Isacco Ferrarini, Francesco Merli, et al.
Hemasphere
|
April 10, 2023
Role of Rituximab Addition to First-line Chemotherapy Regimens in Nodular Lymphocyte-predominant Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi
Manuel Gotti, Roberta Sciarra, Alessandro Pulsoni, et al.
Oncotarget
|
December 7, 2017
Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma
Cinzia Pellegrini, Alessandro Broccoli, Alessandro Pulsoni, et al.
Page
of 12
Search research articles
Search
Showing results (101-110 of 117) with videos related to
Sort By:
Page
of 12
Clinical Lymphoma, Myeloma & Leukemia
|
June 26, 2025
Health-Related Quality of Life With Odronextamab Monotherapy for Relapsed/Refractory Follicular Lymphoma in the ELM-2 Study
Benoit Tessoulin, James Harnett, Seok-Goo Cho, et al.
Oncotarget
|
May 29, 2018
Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma
Alessandro Broccoli, Beatrice Casadei, Alice Morigi, et al.
Leukemia
|
August 30, 2022
Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients
Barbara Mora, Paola Guglielmelli, Andrew Kuykendall, et al.
Hematological Oncology
|
May 25, 2022
Ibrutinib dose intensity in high-risk chronic lymphocytic leukemia
Gabriela Forestieri, Lodovico Terzi di Bergamo, Marina Deodato, et al.
Blood Advances
|
June 5, 2023
A Fondazione Italiana Linfomi cohort study of R-COMP vs R-CHOP in older patients with diffuse large B-cell lymphoma
Annalisa Arcari, Lugi Rigacci, Alessandra Tucci, et al.
British Journal of Haematology
|
November 9, 2018
Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death
Carlo Visco, Maria C Tisi, Andrea Evangelista, et al.
Eclinicalmedicine
|
April 18, 2024
Marginal zone lymphoma international prognostic index: a unifying prognostic index for marginal zone lymphomas requiring systemic treatment
Luca Arcaini, Côme Bommier, Juan Pablo Alderuccio, et al.
Hematological Oncology
|
October 20, 2022
SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort
Michele Merli, Isacco Ferrarini, Francesco Merli, et al.
Hemasphere
|
April 10, 2023
Role of Rituximab Addition to First-line Chemotherapy Regimens in Nodular Lymphocyte-predominant Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi
Manuel Gotti, Roberta Sciarra, Alessandro Pulsoni, et al.
Oncotarget
|
December 7, 2017
Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma
Cinzia Pellegrini, Alessandro Broccoli, Alessandro Pulsoni, et al.
Page
of 12